{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:03:51Z","timestamp":1780113831897,"version":"3.54.0"},"reference-count":18,"publisher":"Tottori University Faculty of Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.33160\/yam.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T22:08:47Z","timestamp":1779574127000},"page":"223-227","source":"Crossref","is-referenced-by-count":0,"title":["Topiramate-Responsive Myoclonic Status Epilepticus in a Child with Progressive Myoclonus Epilepsy Due to Neuronal Ceroid Lipofuscinosis Type 8: A Case Report"],"prefix":"10.33160","volume":"69","author":[{"given":"Hirokazu","family":"Tsuchie","sequence":"first","affiliation":[{"name":"Division of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Kawanami","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Okanishi","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Maegaki","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Brain and Neurosciences, School of Medicine, Faculty of medicine, Tottori University, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Orsini A, Valetto A, Bertini V, Esposito M, Carli N, Minassian BA, et al. The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy. Seizure. 2019;71:247-57. PMID:31476531, DOI:10.1016\/j.seizure.2019.08.012","DOI":"10.1016\/j.seizure.2019.08.012"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Miyahara A, Saito Y, Sugai K, Nakagawa E, Sakuma H, Komaki H, et al. Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus. Epilepsy Res. 2009;84:201-9. PMID:19268538, DOI:10.1016\/j.eplepsyres.2009.02.010","DOI":"10.1016\/j.eplepsyres.2009.02.010"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Iivanainen M, Himberg JJ. Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol. 1982;39:236-8. PMID:6803743, DOI:10.1001\/archneur.1982.00510160042008","DOI":"10.1001\/archneur.1982.00510160042008"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Vossler DG, Conry JA, Murphy JV; ZNS-502\/505 PME Study Group. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open\u2010label study. Epileptic Disord. 2008;10:31-4. PMID:18367429, DOI:10.1684\/epd.2008.0168","DOI":"10.1684\/epd.2008.0168"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Papacostas S, Kkolou E, Papathanasiou E. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci. 2007;29:164-6. PMID:17242859, DOI:10.1007\/s11096-006-9039-1","DOI":"10.1007\/s11096-006-9039-1"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Aykutlu E, Baykan B, G\u00fcrses C, Bebek N, B\u00fcy\u00fckbabani N, G\u00f6kyig\u02c7it A. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav. 2005;6:260-3. PMID:15710314, DOI:10.1016\/j.yebeh.2004.11.014","DOI":"10.1016\/j.yebeh.2004.11.014"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Demir CF, \u00d6zdemir HH, M\u00fcngen B. Efficacy of topiramate as add-on therapy in two different types of progressive myoclonic epilepsy. Acta Medica (Hradec Kralove). 2013;56:36-8. PMID:23909054, DOI:10.14712\/18059694.2014.37","DOI":"10.14712\/18059694.2014.37"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Fedi M, Reutens D, Dubeau F, Andermann E, D\u2019Agostino D, Andermann F. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol. 2001;58:781-6. PMID:11346373, DOI:10.1001\/archneur.58.5.781","DOI":"10.1001\/archneur.58.5.781"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Dirani M, Nasreddine W, Abdulla F, Beydoun A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2014;2:164-6. PMID:25667898, DOI:10.1016\/j.ebcr.2014.09.003","DOI":"10.1016\/j.ebcr.2014.09.003"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Wallace SJ. Myoclonus and epilepsy in childhood: A review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147-54. PMID:9477147, DOI:10.1016\/S0920-1211(97)00080-6","DOI":"10.1016\/S0920-1211(97)00080-6"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. K\u00e4lvi\u00e4inen R, Genton P, Andermann E, Andermann F, Magaudda A, Frucht SJ, et al. Brivaracetam in Unverricht\u2010Lundborg disease ( EPM 1): results from two randomized, double\u2010blind, placebo\u2010controlled studies. Epilepsia. 2016;57:210-21. PMID:26666500, DOI:10.1111\/epi.13275","DOI":"10.1111\/epi.13275"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Lasek-Bal A, Lukasik M, \u017bak A, Sulek A, Bosak M. Unverricht-Lundborg disease: clinical course and seizure management based on the experience of polish centers. Seizure. 2019;69:87-91. PMID:30999254, DOI:10.1016\/j.seizure.2019.04.008","DOI":"10.1016\/j.seizure.2019.04.008"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Roivainen R, Karvonen MK, Puumala T. Seizure control in Unverricht\u2010Lundborg disease: a single\u2010centre study. Epileptic Disord. 2014;16:191-5. PMID:24777117, DOI:10.1684\/epd.2014.0654","DOI":"10.1684\/epd.2014.0654"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Michelucci R, Pasini E, Riguzzi P, Andermann E, K\u00e4lvi\u00e4inen R, Genton P. Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials. Epileptic Disord. 2016;18(suppl 2):145-53. PMID:27629998, DOI:10.1684\/epd.2016.0861","DOI":"10.1684\/epd.2016.0861"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Badura-Stronka M, Winczewska-Wiktor A, Pietrzak A, Hirschfeld AS, Zemojtel T, Wo\u0142y\u0144ska K, et al. CLN8 mutations presenting with a phenotypic continuum of neuronal ceroid lipofuscinosis-literature review and case report. Genes (Basel). 2021;12:956. PMID:34201538, DOI:10.3390\/genes12070956","DOI":"10.3390\/genes12070956"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Baltar F, Simoes C, Garagorry F, Gra\u00f1a M, Rodr\u00edguez S, Hayd\u00e9e Aunchayna M, et al. Two compound heterozygous variants in the CLN8 gene are responsible for neuronal cereidolipofuscinoses disorder in a child: a case report. Front Pediatr. 2024;12:1379254. PMID:38751748, DOI:10.3389\/fped.2024.1379254","DOI":"10.3389\/fped.2024.1379254"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Sharkia R, Zalan A, Zahalka H, Kessel A, Asaly A, Al-Shareef W, et al. CLN8 gene compound heterozygous variants: a new case and protein bioinformatics analyses. Genes (Basel). 2022;13:1393. PMID:36011304, DOI:10.3390\/genes13081393","DOI":"10.3390\/genes13081393"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kielar C, Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA, et al. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis. 2007;25:150-62. PMID:17046272, DOI:10.1016\/j.nbd.2006.09.001","DOI":"10.1016\/j.nbd.2006.09.001"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/69\/2\/69_2026.05.009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:23:40Z","timestamp":1780111420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/69\/2\/69_2026.05.009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2026.05.009","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"2026.05.009"}}